PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL
The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
1 .- 20 . (canceled)
21 . A composition comprising a compound of formula (XVI):
or a pharmaceutically acceptable salt thereof,
wherein said composition comprises at least 99.96 area % of the compound of formula (XVI) and less than 0.04 area % of 4,6-dihalo-5-pentylbenzene-1,3-diol, 4-halo-5-pentylbenzene-1,3-diol, 6-halo-5-pentylbenzene-1,3-diol, and delta-9-tetrahydrocannabinol.
22 . The composition of claim 21 , wherein said composition is a white crystalline powder.
23 . The composition of claim 21 , wherein said halo is chloro or bromo.
24 . The composition of claim 23 , wherein said halo is bromo.
25 . The composition of claim 24 , comprising a compound of formula (XVI):
or a pharmaceutically acceptable salt thereof,
wherein said composition comprises at least 99.96 area % of the compound of formula (XVI) and less than 0.04 area % of 4-bromo-5-pentylbenzene-1,3-diol, 6-bromo-5-pentylbenzene-1,3-diol, and delta-9-tetrahydrocannabinol.
26 . The composition of claim 21 , wherein said compound of formula (XVI) has an enantiomeric excess of at least about 99%.
27 . A composition comprising a compound of formula (XVI):
or a pharmaceutically acceptable salt thereof;
wherein said composition comprises no more than 400 ppm of 4,6-dihalo-5-pentylbenzene-1,3-diol, 4-halo-5-pentylbenzene-1,3-diol, 6-halo-5-pentylbenzene-1,3-diol, and delta-9-tetrahydrocannabinol.
28 . The composition of claim 27 , wherein said halo is chloro or bromo.
29 . The composition of claim 28 , wherein said halo is bromo.
30 . The composition of claim 29 , comprising no more than 400 ppm of 4-bromo-5-pentylbenzene-1,3-diol, 6-bromo-5-pentylbenzene-1,3-diol, and delta-9-tetrahydrocannabinol
31 . The composition of claim 27 , wherein said composition is a white crystalline powder.
32 . The composition of claim 27 , wherein said compound of formula (XVI) has an enantiomeric excess of at least about 99%.